Celgene Corp has agreed to pay the privately-held Agios Pharmaceuticals Inc of Cambridge, Massachusetts $130 million upfront, including an equity investment, for access to Agios’s cancer metabolism research platform. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
